All Outputs (54)

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma (2017)
Journal Article
Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P., & Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. British journal of haematology, 182(3), 429-433. https://doi.org/10.1111/bjh.14793

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL (2017)
Journal Article
Howard, D. R., Munir, T., McParland, L., Rawstron, A. C., Milligan, D., Schuh, A., Hockaday, A., Allsup, D. J., Marshall, S., Duncombe, A. S., O'Dwyer, J. L., Smith, A. F., Longo, R., Varghese, A., & Hillmen, P. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 31(11), 2416-2425. https://doi.org/10.1038/leu.2017.96

© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontli... Read More about Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia (2017)
Journal Article
Law, P. J., Berndt, S. I., Speedy, H. E., Camp, N. J., Sava, G. P., Skibola, C. F., Holroyd, A., Joseph, V., Sunter, N. J., Nieters, A., Bea, S., Monnereau, A., Martin-Garcia, D., Goldin, L. R., Clot, G., Teras, L. R., Quintela, I., Birmann, B. M., Jayne, S., Cozen, W., …Slager, S. (2017). Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature communications, 8, 14175. https://doi.org/10.1038/ncomms14175

Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis of six genome-wide association studies, imputed using a merged reference pan... Read More about Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci (2017)
Journal Article
Law, P. J., Sud, A., Mitchell, J. S., Henrion, M., Orlando, G., Lenive, O., Broderick, P., Speedy, H. E., Johnson, D. C., Kaiser, M., Weinhold, N., Cooke, R., Sunter, N. J., Jackson, G. H., Summerfield, G., Harris, R. J., Pettitt, A. R., Allsup, D. J., Carmichael, J., Bailey, J. R., …Houlston, R. S. (2017). Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific reports, 7, 41071. https://doi.org/10.1038/srep41071

B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been identified, an agnostic, genome-wide search for s... Read More about Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial (2016)
Journal Article
Howard, D. R., Munir, T., Hockaday, A., Rawstron, A. C., Collett, L., Oughton, J. B., Allsup, D., Bloor, A., Phillips, D., & Hillmen, P. (2016). Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17(1), Article 456. https://doi.org/10.1186/s13063-016-1581-0

Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Combination immunochemotherapy such as fludarabine, cyclophosphamide and rituximab is the standard first line therapy in fit patients, but there is limited evidence r... Read More about Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.

Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects (2016)
Journal Article
Johnson, B., Lowe, G. C., Futterer, J., Lordkipanidzé, M., Macdonald, D., Simpson, M. A., Sanchez-Guiú, I., Drake, S., Bem, D., Leo, V., Fletcher, S. J., Dawood, B., Rivera, J., Allsup, D., Biss, T., Bolton-Maggs, P. H. B., Collins, P., Curry, N., Grimley, C., James, B., …on behalf of the UK GAPP Study Group. (2016). Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica, 101(10), 1170-1179. https://doi.org/10.3324/haematol.2016.146316

© 2016 Ferrata Storti Foundation. Inherited thrombocytopenias are a heterogeneous group of disorders characterized by abnormally low platelet counts which can be associated with abnormal bleeding. Next-generation sequencing has previously been employ... Read More about Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects.

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease (2014)
Journal Article
Lin, T. T., Norris, K., Heppel, N. H., Pratt, G., Allan, J. M., Allsup, D. J., Bailey, J., Cawkwell, L., Hills, R., Grimstead, J. W., Jones, R. E., Britt-Compton, B., Fegan, C., Baird, D. M., & Pepper, C. (2014). Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British journal of haematology, 167(2), 214-223. https://doi.org/10.1111/bjh.13023

© 2014 John Wiley & Sons Ltd. Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. Here we assessed the ability of high-resolution single telomere length analysis (STELA), combined with an experimentally d... Read More about Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease.

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia (2013)
Journal Article
Speedy, H. E., Di Bernardo, M. C., Sava, G. P., Dyer, M. J. S., Holroyd, A., Wang, Y., Sunter, N. J., Mansouri, L., Juliusson, G., Smedby, K. E., Roos, G., Jayne, S., Majid, A., Dearden, C., Hall, A. G., Mainou-Fowler, T., Jackson, G. H., Summerfield, G., Harris, R. J., Pettitt, A. R., …Houlston, R. S. (2014). A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature genetics, 46(1), 56-60. https://doi.org/10.1038/ng.2843

Genome-wide association studies (GWAS) of chronic lymphocytic leukemia (CLL) have shown that common genetic variation contributes to the heritable risk of CLL. To identify additional CLL susceptibility loci, we conducted a GWAS and performed a meta-a... Read More about A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.

Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen (2013)
Journal Article
Kashuba, E., Eagle, G. L., Bailey, J., Evans, P., Welham, K. J., Allsup, D., & Cawkwell, L. (2013). Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. Journal of Proteomics, 91, 478-485. https://doi.org/10.1016/j.jprot.2013.08.002

CLL is an incurable disease with variable prognosis. The hyper reactivity of the B-cell receptor (BCR) to unknown antigen ligation plays a pivotal role in CLL-cell survival. We aimed to investigate the BCR signalling pathway using proteomics to ident... Read More about Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen.

The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy (2013)
Journal Article
Mazumdar, R., Evans, P., Culpin, R., Bailey, J., & Allsup, D. (2013). The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. Leukemia Research, 37(6), 614-618. https://doi.org/10.1016/j.leukres.2013.02.020

We conducted an analysis of the effect of monocytosis at diagnosis of CLL on subsequent overall (OS) and treatment-free survival (TFS). Monocyte counts were performed using the Sysmex XE2100™ analyser. A monocyte count >0.91×109L-1 at the time of dia... Read More about The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy.

Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours (2012)
Journal Article
Madden, L. A., Hayman, Y. A., Underwood, C., Vince, R. V., Greenman, J., Allsup, D., & Ali, S. (2012). Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours. Scandinavian journal of clinical & laboratory investigation, 72(5), 380-386. https://doi.org/10.3109/00365513.2012.681683

Background. Heat shock protein 72 (Hsp72) is a highly inducible stress protein and molecular chaperone. Cancers have been shown to be associated with increased Hsp72 expression within the tumour itself and this may lead to resistance to apoptosis. Me... Read More about Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours.

Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism (2010)
Journal Article
Whittle, A. M., Allsup, D. J., & Bailey, J. R. (2011). Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leukemia Research, 35(3), 419-421. https://doi.org/10.1016/j.leukres.2010.11.011

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer patients. The literature is sparse on the incidence in the most common lymphoid malignancy, chronic lymphocytic leukaemia (CLL). We calculated the incidence rates for... Read More about Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism.

Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells (2010)
Journal Article
Pointon, J. C., Eagle, G., Bailey, J., Evans, P., Allsup, D., & Greenman, J. (2010). Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells. Oncology Reports, 24(5), 1315-1321. https://doi.org/10.3892/or_00000988

Numerous chemotherapeutic regimens exist for the treatment of symptomatic or progressive chronic lymphocytic leukaemia (CLL). However, once the disease becomes refractory to nucleoside-based therapy the prognosis is poor. In this study we investigate... Read More about Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells.

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk (2010)
Journal Article
Crowther-Swanepoel, D., Broderick, P., Di Bernardo, M. C., Dobbins, S. E., Torres, M., Mansouri, M., Ruiz-Ponte, C., Enjuanes, A., Rosenquist, R., Carracedo, A., Jurlander, J., Campo, E., Juliusson, G., Montserrat, E., Smedby, K. E., Dyer, M. J., Matutes, E., Dearden, C., Sunter, N. J., Hall, A. G., …Houlston, R. S. (2010). Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature genetics, 42(2), 132-136. https://doi.org/10.1038/ng.510

To identify new risk variants for chronic lymphocytic leukemia (CLL), we conducted a genome-wide association study of 299,983 tagging SNPs, with validation in four additional series totaling 2,503 cases and 5,789 controls. We identified four new risk... Read More about Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.